Hypertriglyceridemia in cardiac rehabilitation-A residual risk worth targeting?
- PMID: 40848852
- DOI: 10.1016/j.ijcard.2025.133787
Hypertriglyceridemia in cardiac rehabilitation-A residual risk worth targeting?
Conflict of interest statement
Declaration of competing interest Dr. Aggarwal is involved in research funded by the Bristol Myers Squibb-Pfizer alliance, Novartis, Lexicon, Cleerly, and Amarin, and is a consultant for Lexicon and Amarin. Dr. Nelson: Speakers bureau for Amarin, Amgen, and Esperion; stock shareholder for Amgen; advisory board for Amarin. Dr. Philip: Employment and stock shareholder of Amarin.
Publication types
LinkOut - more resources
Full Text Sources